AstraZeneca Results Presentation Deck
H1 2021: growth profile enhanced
Key highlights
Total revenue +18%, incl. 9% from the pandemic COVID-19¹ vaccine. Total revenue excl. vaccine +9%
Q2 growth 12% excl. vaccine
Growth: Oncology +15% and New CVRM² +16 %. Respiratory & Immunology +6%. Emerging markets +21%
Core operating profit +20%, supported by core 001³ (+115%)
Core EPS4 $2.53 (+27%), incl. 14% tax rate. Impact of pandemic vaccine $(0.04)
Pipeline news accelerated, incl. close-to-market opportunities
ESG5: large boost in pandemic vaccine; about one billion doses released for supply as of today across the network of collaborators
Alexion acquisition now closed; consolidation well underway
2021 guidance updated: total revenue is expected to increase by a low-twenties percentage, accompanied by a faster growth in core
EPS to $5.05 to $5.40
B
Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for first-half (H1) 2021, unless stated otherwise. Guidance at CER and excludes the pandemic COVID-19 vaccine. 1. Coronavirus disease; an infectious disease
caused by a newly discovered coronavirus 2. New Cardiovascular, Renal & Metabolism comprising Farxiga, Brilinta, Diabetes and Renal 3. Other operating income 4. Earnings per share 5. Environmental, social and (corporate) governance (topics).
5View entire presentation